| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | foretinib | GDSC1000 | pan-cancer | AAC | 0.043 | 0.2 |
| mRNA | trifluoperazine | CTRPv2 | pan-cancer | AAC | -0.052 | 0.2 |
| mRNA | PRL-3 Inhibitor I | CTRPv2 | pan-cancer | AAC | 0.051 | 0.2 |
| mRNA | Platin | CTRPv2 | pan-cancer | AAC | 0.05 | 0.2 |
| mRNA | 17-AAG | GDSC1000 | pan-cancer | AAC | 0.043 | 0.2 |
| mRNA | regorafenib | CTRPv2 | pan-cancer | AAC | -0.05 | 0.2 |
| mRNA | GDC-0879 | CTRPv2 | pan-cancer | AAC | -0.047 | 0.2 |
| mRNA | SZ4TA2 | CTRPv2 | pan-cancer | AAC | 0.073 | 0.2 |
| mRNA | SNX-2112:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.044 | 0.2 |
| mRNA | BRD-K96431673 | CTRPv2 | pan-cancer | AAC | -0.096 | 0.2 |